# EDGAR Filing Document

**Accession Number:** 0001621227
**File Stem:** 0001104659-25-110847
**Filing Date:** 2025-11
**Character Count:** 3059
**Document Hash:** c3f4e2b630a94028f45ec8be7ed90b27
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-110847.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001104659-25-110847

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**EFFECTIVENESS DATE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adaptimmune Therapeutics PLC
- **CENTRAL INDEX KEY:** 0001621227
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37368
- **FILM NUMBER:** 251475406

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 JUBILEE AVENUE
- **STREET 2:** MILTON PARK
- **CITY:** ABINGDON, OXFORDSHIRE
- **PROVINCE COUNTRY:** X0
- **BUSINESS PHONE:** 44 1235 430000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 JUBILEE AVENUE
- **STREET 2:** MILTON PARK
- **CITY:** ABINGDON, OXFORDSHIRE
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adaptimmune Ltd
- **DATE OF NAME CHANGE:** 20141001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION**

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number 001-37368**

Adaptimmune Therapeutics plc

**(Exact name of registrant as specified in its charter)**

**60 Jubilee Avenue,<br> Milton Park Abingdon, Oxfordshire OX14 4RX<br> United Kingdom<br> (44) 1235 430000**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**American Depositary Shares, each representing six ordinary shares, par value £0.001 per share**

**(Title of each class of securities covered by this Form)**

**None** 

**(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)**

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ⌧ |
| Rule 12g-4(a)(2) | ¨ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ¨ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: 25.

Pursuant to the requirements of the Securities Exchange Act of 1934, Adaptimmune Therapeutics plc has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| By: | /s/ Adrian Rawcliffe | /s/ Adrian Rawcliffe |
|  | Name: | Adrian Rawcliffe |
|  | Title: | Chief Executive Officer |

---

Date: November 13, 2025